ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind.
ZBH - Zimmer Biomet Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$103.11
DETAILS
HIGH:
$120.00
LOW:
$93.00
MEDIAN:
$104.00
CONSENSUS:
$103.11
UPSIDE:
4.62%
Stock News
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
WARSAW, Ind., Oct. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webcast on Wednesday, November 4, 2026, at 8:30 a.m.
Critical Review: Zimmer Biomet (NYSE:ZBH) and Butterfly Network (NYSE:BFLY)
Zimmer Biomet (NYSE: ZBH - Get Free Report) and Butterfly Network (NYSE: BFLY - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Analyst Ratings This is a summary of recent
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend
Zimmer Biomet Holdings, Inc. (NYSE: ZBH - Get Free Report) declared a quarterly dividend on Friday, August 28th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.24 per share by the medical equipment provider on Friday, October 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The
Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by State Street Corp
State Street Corp boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 0.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,877,171 shares of the medical equipment provider's stock after acquiring an additional 52,044 shares during
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV)
Zimmer Biomet (NYSE: ZBH - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Profitability This table compares Zimmer Biomet and CapsoVision's net
Is Zimmer Biomet Holdings Inc (ZBH) a Bargain After 3.9% Drop? GF Value Says Undervalued
On September 08, 2026, Zimmer Biomet Holdings Inc (ZBH) shares fell 3.9% to a current price of $94.22. This decline comes amid a 52-week price range of $79.12 t
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
25,021 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Jupiter Topco LLC
Jupiter Topco LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 25,021 shares of the medical equipment provider's stock, valued at approximately $2,156,000. Other institutional investors and hedge funds have
Zimmer Biomet - Showing Signs Of Life
Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026.
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
Zimmer Biomet Q2 Earnings Call Highlights
Zimmer Biomet (NYSE: ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constant-currency sales rose 4.6%, while international sales increased 3.1%. Chairman, President and
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zimmer Biomet Q2 Earnings Call Highlights
Zimmer Biomet NYSE: ZBH reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.
Price Targets
Zimmer Biomet price target raised to $100 from $83 at Canaccord
$100.00
(was $96.55)
Caitlin Cronin
·
Canaccord Genuity
Zimmer Biomet price target raised to $106 from $92 at Truist
$106.00
(was $96.61)
Truist Financial
Zimmer Biomet price target raised to $104 from $92 at Baird
$104.00
(was $97.32)
Robert W. Baird
Zimmer Biomet price target raised to $120 from $115 at UBS
$120.00
(was $97.06)
Patrick Wood
·
UBS
Zimmer Biomet price target raised to $93 from $91 at Bernstein
$93.00
(was $97.53)
Bernstein
Zimmer Biomet price target raised to $96 from $95 at BMO Capital
$96.00
(was $98.16)
BMO Capital
Zimmer Biomet price target raised to $110 from $101 at RBC Capital
$110.00
(was $98.16)
Kendall Au
·
RBC Capital
Zimmer Biomet upgraded to Buy from Sell at UBS
$115.00
(was $92.07)
Patrick Wood
·
UBS
Zimmer Biomet initiated with a Market Perform at BMO Capital
$95.00
(was $87.56)
BMO Capital
Zimmer Biomet price target lowered to $92 from $98 at Truist
$92.00
(was $80.80)
Truist Financial
Zimmer Biomet price target lowered to $83 from $93 at Canaccord
$83.00
(was $82.80)
Canaccord Genuity
Zimmer Biomet price target lowered to $105 from $110 at Stifel
$105.00
(was $82.80)
Rick Wise
·
Stifel Nicolaus
Zimmer Biomet price target lowered to $92 from $100 at Baird
$92.00
(was $82.80)
Robert W. Baird
Zimmer Biomet price target lowered to $94 from $100 at Barclays
$94.00
(was $82.80)
Matt Miksic
·
Barclays
Zimmer Biomet price target lowered to $100 from $104 at Barclays
$100.00
(was $96.69)
Matt Miksic
·
Barclays
Zimmer Biomet price target raised to $89 from $86 at UBS
$89.00
(was $93.69)
UBS
Zimmer Biomet price target lowered to $86 from $88 at UBS
$86.00
(was $85.27)
UBS
Zimmer Biomet price target raised to $99 from $97 at Bernstein
$99.00
(was $94.08)
Bernstein
Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
$93.00
(was $94.08)
David Roman
·
Goldman Sachs
Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI
$120.00
(was $90.02)
Evercore ISI